(Reuters) -INmune Bio said on Monday its experimental Alzheimer’s drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its shares plunging nearly 59% in premarket trading.
(Reporting by Mariam Sunny in Bengaluru; Editing by Alan Barona and Sriraj Kalluvila)
